248,628 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Nuveen LLC

Nuveen LLC acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 248,628 shares of the company’s stock, valued at approximately $3,352,000. Nuveen LLC owned 0.30% of Viridian Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Amalgamated Bank raised its stake in Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after acquiring an additional 840 shares during the period. GAMMA Investing LLC raised its stake in Viridian Therapeutics by 3,892.9% during the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock worth $114,000 after acquiring an additional 8,214 shares during the period. Brevan Howard Capital Management LP acquired a new stake in Viridian Therapeutics during the fourth quarter worth about $258,000. Nebula Research & Development LLC acquired a new stake in Viridian Therapeutics during the fourth quarter worth about $328,000. Finally, ProShare Advisors LLC grew its position in Viridian Therapeutics by 74.1% in the 4th quarter. ProShare Advisors LLC now owns 20,584 shares of the company’s stock worth $395,000 after purchasing an additional 8,761 shares during the last quarter.

Viridian Therapeutics Trading Down 0.5%

Viridian Therapeutics stock opened at $18.56 on Thursday. The firm has a 50 day simple moving average of $16.80 and a 200-day simple moving average of $15.15. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.01 and a quick ratio of 11.01. The stock has a market capitalization of $1.52 billion, a PE ratio of -4.85 and a beta of 0.42. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.00). The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The business’s revenue was up 4.2% on a year-over-year basis. During the same period last year, the firm posted ($0.81) earnings per share. As a group, equities research analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on VRDN. Wells Fargo & Company decreased their target price on shares of Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Needham & Company LLC decreased their target price on shares of Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. The Goldman Sachs Group upped their target price on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. JMP Securities decreased their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 7th. Finally, Jefferies Financial Group began coverage on shares of Viridian Therapeutics in a research report on Monday. They issued a “buy” rating and a $44.00 target price for the company. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.78.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.